Provectus Biopharmaceuticals, Inc.
PVCT
$0.05
$0.00-0.75%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 45.84% | -13.19% | 50.79% | -29.27% | -114.27% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -77.27% | -77.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.09% | 0.56% | -76.51% | 2,522.69% | 2,415.25% |
| Change in Net Operating Assets | -68.62% | 340.72% | -100.84% | -63.51% | 1,313.94% |
| Cash from Operations | 31.52% | 67.29% | 4.65% | -48.65% | 31.41% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 151.85% | -26.37% | 79.09% | -20.30% | -19.40% |
| Total Debt Repaid | 1.99% | 2.20% | -40.91% | 54.89% | 13.33% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -89.29% | -50.00% | -- | -- |
| Cash from Financing | 174.84% | -69.26% | 32.95% | -15.86% | -20.24% |
| Foreign Exchange rate Adjustments | -75.00% | 200.00% | 111.11% | -100.00% | 100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,860.38% | -34.98% | 243.61% | -1,481.53% | 69.45% |